Brief: Alvotech And Teva Announce Acceptance Of U.S. Biologics License Application For Avt04
06/01/2023 09:02
Jan 6 (Reuters) - Alvotech Sa ALVO.O :
* ALVOTECH AND TEVA ANNOUNCE ACCEPTANCE OF U.S. BIOLOGICS
LICENSE
APPLICATION FOR AVT04, A PROPOSED BIOSIMILAR TO STELARA®
(USTEKINUMAB)
* U.S. FOOD AND DRUG ADMINISTRATION'S (FDA) REGULATORY
REVIEW IS
ANTICIPATED TO BE COMPLETED IN SECOND HALF OF 2023
Source text for Eikon: ID:nGNX57qQZL
Further company coverage: ALVO.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Alvotech SA
See all newsBrief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Brief: Alvotech and Teva Secure U.S. Settlement Date For AVT06
India's Dr Reddy's rises after EU marketing authorisation for osteoporosis biosimilar
Brief: UK High Court Rules In Favor Of Alvotech Paving Way For AVT06, Biosimilar To Eylea
U.S. STOCKS ON THE MOVE-Cummins, EPAM Systems, Qualcomm